Afuco™ Anti-CD38 ADCC Therapeutic Antibody (Daratumumab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug. It binds to CD38.
Supplier Creative Biolabs
Product # AFC-TAB-236
Pricing Inquiry
Host Human
Target CD38
Species Reactivity Human
Type ADCC enhanced antibody
Applications IP, IF, FuncS, FC, Neut, ELISA
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback